2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non–Small-Cell Lung Cancer

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.

          The JIPANG study is an open-label phase III trial evaluating the efficacy of pemetrexed plus cisplatin (PemP) versus vinorelbine plus cisplatin (NP) as adjuvant chemotherapy in patients with stage II-IIIA nonsquamous non–small-cell lung cancer (NSCLC). Here, we report the long follow-up overall survival (OS) data. Eligible patients were randomly assigned to receive either PemP or NP. The primary end point was recurrence-free survival (RFS), and the secondary end point included OS. This analysis was performed using data collected 5 years after the last patient enrollment. Among 804 patients enrolled, 783 patients were eligible (384 for NP and 389 for PemP). The updated median RFS was 37.5 months in the NP arm and 43.4 months in the PemP arm with a hazard ratio of 0.95 (95% CI, 0.79 to 1.14). At a median follow-up of 77.3 months, the OS rates at 3 and 5 years were 84.1% and 75.6% versus 87.0% and 75.0% with a hazard ratio of 1.04 (95% CI, 0.81 to 1.34). This long-term follow-up analysis showed that PemP had similar efficacy to NP in both RFS and OS for this population, with one of the longest OS data compared with the historical data.

          Related collections

          Most cited references15

          • Record: found
          • Abstract: found
          • Article: not found

          Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

          Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

            First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the first-line treatment of choice. The addition of pembrolizumab to chemotherapy resulted in significantly higher rates of response and longer progression-free survival than chemotherapy alone in a phase 2 trial.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

              The cancer-cell-killing property of atezolizumab may be enhanced by the blockade of vascular endothelial growth factor-mediated immunosuppression with bevacizumab. This open-label, phase 3 study evaluated atezolizumab plus bevacizumab plus chemotherapy in patients with metastatic nonsquamous non-small-cell lung cancer (NSCLC) who had not previously received chemotherapy.
                Bookmark

                Author and article information

                Contributors
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                Journal
                Journal of Clinical Oncology
                JCO
                American Society of Clinical Oncology (ASCO)
                0732-183X
                1527-7755
                December 01 2023
                December 01 2023
                : 41
                : 34
                : 5242-5246
                Affiliations
                [1 ]Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi-cho Sunto-gun, Japan
                [2 ]Internal Medicine III, Wakayama Medical University, Wakayama, Japan
                [3 ]Department of Data Science, National Cancer Center Hospital East, Kashiwa, Japan
                [4 ]Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
                [5 ]Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan
                [6 ]Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan
                [7 ]Department of Thoracic Surgery, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
                [8 ]Department of Medical Oncology, Faculty of Medicine, Kindai University, Osaka, Japan
                [9 ]Department of Thoracic and Breast Surgery, Oita University, Oita, Japan
                [10 ]Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
                [11 ]Department of General Thoracic Surgery, Breast and Endocrinological Surgery, Okayama University, Okayama, Japan
                [12 ]Department of Thoracic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan
                [13 ]Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan
                [14 ]Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
                [15 ]Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
                [16 ]Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
                [17 ]Department of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, Yokohama, Japan
                [18 ]Department of Medical Oncology, Chiba University Hospital, Chiba, Japan
                [19 ]Division of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Japan
                Article
                10.1200/JCO.23.00179
                37656928
                9ed04dad-48ba-4de8-aceb-48f55e9a39ca
                © 2023
                History

                Comments

                Comment on this article